Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session. (HOTAIR2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02009813 |
Recruitment Status :
Completed
First Posted : December 12, 2013
Last Update Posted : December 2, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity Type 2 Diabetes | Procedure: Hyperbaric Oxygen Therapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 9 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session. |
Study Start Date : | March 2013 |
Actual Primary Completion Date : | March 2014 |
Actual Study Completion Date : | March 2014 |

- Procedure: Hyperbaric Oxygen Therapy
Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
- Insulin sensitivity [ Time Frame: 2 hours ]
- Hypoxia and inflammatory markers [ Time Frame: 2 hours ]Using immuno-histo chemistry (IHC), quantitative plymerase chain reaction (qPCR), Western blot

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Overweight to obese (BMI 25-35 kg/m2)
- Age >18 years (no specific upper age limit)
- Fit to enter hyperbaric chamber as assessed by hyperbaric physician.
Exclusion Criteria:
- Personal history of Diabetes
- Personal history of major psychiatric disorders
- UIse of prescribed or non-prescribed medications which may affect glucose homeostasis (e.g. steroids),
- Uncontrolled asthma,
- Current fever or upper respiratory infections
- Individuals who regularly perform high intensity exercise (>2 week),
- Pregnancy, lactation and women who are planning to become pregnant
- Current intake of >140g alcohol/week,
- Current smokers of cigarettes/cigars/marijuana,
- Current inatke of any illicit substance,
- Claustrophobia
- has donated blood within past 3 months.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02009813
Australia, South Australia | |
Royal Adelaide Hospital | |
Adelaide, South Australia, Australia, 5000 |
Principal Investigator: | Leonie K Heilbronn, PhD | University of Adelaide | |
Principal Investigator: | David Wilkinson, BMBS | University of Adelaide |
Responsible Party: | A/Prof Leonie Heilbronn, A/Prof, University of Adelaide |
ClinicalTrials.gov Identifier: | NCT02009813 |
Other Study ID Numbers: |
RAH121212a |
First Posted: | December 12, 2013 Key Record Dates |
Last Update Posted: | December 2, 2015 |
Last Verified: | November 2015 |
Insulin resistance Inflammation Hypoxia |
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |